FDA Advisory Committee Delivers Overwhelmingly Positive Vote

Replimune Group, Inc. (REPL) has received a highly favorable recommendation from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) for Tudriqev (vusolimogene oderparepvec, RP1), its investigational therapy for advanced melanoma. The committee voted 10 in favor and 3 against, signaling a strong likelihood of approval. This outcome reverses initial skepticism from FDA internal scientists regarding the single-arm clinical trial design. The advisory committee appears to have placed greater emphasis on the significant unmet medical need for alternative treatments for patients who have failed prior anti-PD-1 therapy, outweighing the FDA's more conservative review criteria. This positive development positions Replimune to overcome past setbacks, including Complete Response Letters (CRLs) received in July 2025 and April 2026, and paves the way for regulatory success following its resubmission in June 2026.

Overcoming Limitations of Single-Arm Trial and Demonstrating Efficacy

The Biologics License Application (BLA) is based on the Phase 1/2 IGNYTE trial (NCT03767348), which was conducted without a control arm. FDA reviewers raised concerns about the study's design. Regulators found it difficult to clearly separate the unique effects of Tudriqev, an oncolytic virus directly injected into tumors, from the contribution of Opdivo (nivolumab), which was co-administered. However, the trial results demonstrated a clinically meaningful objective response rate (ORR) of 33.6% and a complete response (CR) rate of 15%, which swayed the advisory committee. The committee concluded that, considering the patients with difficult-to-treat cancers, a response rate of approximately 33% is clinically meaningful and provides sufficient benefit to patients, even in the absence of a control arm.

Regulatory Flexibility Demonstrated Amid White House Intervention Controversy

The third approval attempt for Tudriqev has been a subject of intense interest in the U.S. political and biotech communities. Reports of White House involvement in securing a resubmission opportunity for Replimune raised concerns about the fairness of the regulatory decision-making process. Nevertheless, the advisory committee's decision to vote in favor, based on scientific data and patient needs, is expected to set a precedent for more flexible regulatory approaches to similar single-arm clinical trial designs or virus-based cancer therapies. Market attention now turns to the Prescription Drug User Fee Act (PDUFA) target action date of August 2, 2026, with the expectation that a positive decision will provide a significant boost to the broader biotech sector.

Competition with Amtagvi as a Second-Line Treatment and Market Landscape

The global melanoma treatment market is projected to grow from approximately $11.25 billion in 2026 to over $25.54 billion in 2034, intensifying the competition for second-line treatments. Currently, Iovance Biotherapeutics (IOVA) holds the leading position with Amtagvi (lifileucel), a tumor-infiltrating lymphocyte (TIL) cell therapy that received accelerated approval from the FDA in February 2024. If Tudriqev receives final approval, it could serve as a more convenient and cost-effective alternative to TIL therapy, which is complex and expensive to manufacture. Replimune has secured exclusive commercial rights and plans to leverage its co-development and commercialization agreement with Bristol Myers Squibb (BMS) to accelerate market penetration upon approval.